NEW DELHI: The Indian Council for Medical Research (ICMR) has said that the Indian vaccine against Covid-19, Covaxin, has attracted global attention.
In a tweet, the ICMR said: “India’s indigenous covaxin vaccine # Covid19, a product of the ICMR-Bharat Biotech collaboration, achieves a remarkable feat. Data generated from India underscores the impressive safety profile and immunogenicity of covaxin and sparks the interest of the Lancet in publishing them. ”
The ICMR said: “The encouraging results of the phase I and phase II trials of Covaxin have paved the way for the phase III clinical trial in India, which is currently underway at 22 sites.”
In a tweet, the ICMR said: “India’s indigenous covaxin vaccine # Covid19, a product of the ICMR-Bharat Biotech collaboration, achieves a remarkable feat. Data generated from India underscores the impressive safety profile and immunogenicity of covaxin and sparks the interest of the Lancet in publishing them. ”
The ICMR said: “The encouraging results of the phase I and phase II trials of Covaxin have paved the way for the phase III clinical trial in India, which is currently underway at 22 sites.”
The New Delhi-based Institute of Medical Sciences (AIIMS) invited volunteers for the phase III clinical trial of the indigenously developed Covid-19 vaccine candidate ‘Covaxin’ for which it is one of the sites.
“AIIMS, New Delhi is a site for the Covaxin Phase III clinical trial. This is a full virion inactivated vaccine co-sponsored by the Indian Council for Medical Research (ICMR) and Bharat Biotech,” AIIMS said in an announcement.
AIIMS Center for Community Medicine, Dr. Sanjay K Rai reported through the announcement that Phase I / II trials (safety and immunogenicity) have already been completed.
.
